| CPC A61B 18/06 (2013.01) [A61K 9/0019 (2013.01); A61K 9/0034 (2013.01); A61K 31/165 (2013.01); A61K 47/64 (2017.08); A61M 37/00 (2013.01); A61P 13/12 (2018.01); A61P 25/00 (2018.01); C12Y 302/01017 (2013.01); A61B 2018/0022 (2013.01); A61B 2018/00404 (2013.01); A61B 2018/00434 (2013.01); A61B 2018/00511 (2013.01); A61B 2018/00577 (2013.01); A61M 2025/1015 (2013.01); A61M 2025/1052 (2013.01)] | 20 Claims |

|
1. A method comprising:
intravascularly positioning a first catheter comprising a first expandable member within a renal artery of a patient;
intravascularly positioning a second catheter comprising a second expandable member within a renal vein of the patient, wherein the renal artery and the renal vein are connected to a kidney of the patient;
expanding the first expandable member to substantially occlude blood flow through the renal artery;
expanding the second expandable member to substantially occlude blood flow through the renal vein;
perfusing a perfusate solution through the kidney of the patient; and
administering a neuromodulatory agent through the kidney via at least one of the first catheter or the second catheter to neuromodulate renal nerves in the patient, wherein the neuromodulatory agent comprises a lipophilic agent coupled to an endogenous carrier molecule, and wherein administering the neuromodulatory agent comprises introducing the neuromodulatory agent to the perfusate solution.
|